R J Fox

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury
    Robert J Fox
    Mellen Center for Multiple Sclerosis, 9500 Euclid Ave, U 10, Cleveland, OH 44122, USA
    Arch Neurol 65:1179-84. 2008
  2. ncbi request reprint Pathological mechanisms and disease progression of multiple sclerosis: therapeutic implications
    Carl Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland, Ohio, USA
    Drugs Today (Barc) 38:17-29. 2002
  3. pmc Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS
    Robert J Fox
    Mellen Center for Multiple Sclerosis, Neurological Institute, and Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44122, USA
    Mult Scler 18:1534-40. 2012
  4. ncbi request reprint Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
    Robert J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 367:1087-97. 2012
  5. ncbi request reprint A validation study of multicenter diffusion tensor imaging: reliability of fractional anisotropy and diffusivity values
    R J Fox
    Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio, USA
    AJNR Am J Neuroradiol 33:695-700. 2012
  6. ncbi request reprint Current treatment options in multiple sclerosis
    Adrienne Boissy
    Robert J Fox, MD Mellen Center for Multiple Sclerosis, 9500 Euclid Avenue, U 10, Cleveland, OH 44122, USA
    Curr Treat Options Neurol 9:176-86. 2007
  7. ncbi request reprint Optimal reference population for the multiple sclerosis functional composite
    R J Fox
    Mellen Center for Multiple Sclerosis, Department of Neurology, Cleveland, OH, USA
    Mult Scler 13:909-14. 2007
  8. ncbi request reprint Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury
    R J Fox
    Department of Neurology, Mellen Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mult Scler 14:1036-43. 2008
  9. doi request reprint Measuring myelin repair and axonal loss with diffusion tensor imaging
    R J Fox
    Mellen Center, Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    AJNR Am J Neuroradiol 32:85-91. 2011
  10. pmc Advanced MRI in multiple sclerosis: current status and future challenges
    Robert J Fox
    Mellen Center for Multiple Sclerosis, Neurological Institute, 9500 Euclid Avenue, U 10, Cleveland, OH 44195, USA
    Neurol Clin 29:357-80. 2011

Research Grants

Detail Information

Publications38

  1. ncbi request reprint A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury
    Robert J Fox
    Mellen Center for Multiple Sclerosis, 9500 Euclid Ave, U 10, Cleveland, OH 44122, USA
    Arch Neurol 65:1179-84. 2008
    ..The medial longitudinal fasciculus (MLF) is a key brainstem pathway for ocular adduction and is commonly injured in patients with MS, typically resulting in internuclear ophthalmoparesis...
  2. ncbi request reprint Pathological mechanisms and disease progression of multiple sclerosis: therapeutic implications
    Carl Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland, Ohio, USA
    Drugs Today (Barc) 38:17-29. 2002
  3. pmc Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS
    Robert J Fox
    Mellen Center for Multiple Sclerosis, Neurological Institute, and Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44122, USA
    Mult Scler 18:1534-40. 2012
    ....
  4. ncbi request reprint Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
    Robert J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 367:1087-97. 2012
    ..BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate)...
  5. ncbi request reprint A validation study of multicenter diffusion tensor imaging: reliability of fractional anisotropy and diffusivity values
    R J Fox
    Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio, USA
    AJNR Am J Neuroradiol 33:695-700. 2012
    ..DTI is increasingly being used as a measure to study tissue damage in several neurologic diseases. Our aim was to investigate the comparability of DTI measures between different MR imaging magnets and platforms...
  6. ncbi request reprint Current treatment options in multiple sclerosis
    Adrienne Boissy
    Robert J Fox, MD Mellen Center for Multiple Sclerosis, 9500 Euclid Avenue, U 10, Cleveland, OH 44122, USA
    Curr Treat Options Neurol 9:176-86. 2007
    ..Many new therapies, including oral and infrequently administered infusion therapies, are currently in phase III trials and will likely become available over the next 3 to 4 years...
  7. ncbi request reprint Optimal reference population for the multiple sclerosis functional composite
    R J Fox
    Mellen Center for Multiple Sclerosis, Department of Neurology, Cleveland, OH, USA
    Mult Scler 13:909-14. 2007
    ..These results have significant implications to sample size estimates for longitudinal clinical studies and therapeutic trials...
  8. ncbi request reprint Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury
    R J Fox
    Department of Neurology, Mellen Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mult Scler 14:1036-43. 2008
    ..This observation suggests a CKR "set-point" within individuals, which might relate to inflammatory injury in MS. We evaluated the correlation between CKR levels and magnetic resonance imaging (MRI) measures of disease activity...
  9. doi request reprint Measuring myelin repair and axonal loss with diffusion tensor imaging
    R J Fox
    Mellen Center, Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    AJNR Am J Neuroradiol 32:85-91. 2011
    ..The purpose of our study was to use DTI to evaluate the longitudinal changes in brain tissue integrity in a group of patients with MS...
  10. pmc Advanced MRI in multiple sclerosis: current status and future challenges
    Robert J Fox
    Mellen Center for Multiple Sclerosis, Neurological Institute, 9500 Euclid Avenue, U 10, Cleveland, OH 44195, USA
    Neurol Clin 29:357-80. 2011
    ..Advanced MRI techniques hold promise for filling this void. These imaging tools hold great promise to increase understanding of MS pathogenesis and provide greater insight into the efficacy of new MS therapies...
  11. doi request reprint Advances in the management of PML: focus on natalizumab
    Robert Fox
    Mellen Center for Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Ave, U10, Cleveland, OH 44195, USA
    Cleve Clin J Med 78:S33-7. 2011
    ..High-dose corticosteroids are often recommended if a clinical and imaging syndrome resembling IRIS develops after immune restoration...
  12. ncbi request reprint Treatment of Susac syndrome with gamma globulin and corticosteroids
    Robert J Fox
    Mellen Center, Department of Neurology, U 10, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neurol Sci 251:17-22. 2006
    ..Treatment with IVIg and corticosteroids provides a therapeutic option that avoids the toxicities of chemotherapy and suggests the possible importance of pathologic antibodies in the pathogenesis of Susac syndrome...
  13. ncbi request reprint Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease
    Robert J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:91-102. 2006
    ..Magnetic resonance imaging (MRI) is now integral to the diagnostic process. Treatment of MS can be considered as three parallel pathways: treatment of relapses, symptom management, and long-term prevention of tissue injury...
  14. ncbi request reprint Multiple sclerosis: the importance of early recognition and treatment
    R J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 68:157-71. 2001
    ..Several lines of evidence demonstrate that tissue damage occurs very early in the disease, and much of this damage is clinically silent...
  15. ncbi request reprint Aphemia: an isolated disorder of articulation
    R J Fox
    Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Clin Neurol Neurosurg 103:123-6. 2001
    ..This case suggests that aphemia can occur as an isolated articulation deficit without language involvement or more widespread bulbar apraxia, and may be a severe form of apraxia of speech...
  16. ncbi request reprint New directions in MS therapeutics: vehicles of hope
    Robert J Fox
    The Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Lerner School of Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, U 10, Cleveland, OH 44195, USA
    Trends Immunol 25:632-6. 2004
    ..Dozens of therapies are in various stages of clinical development and results from these clinical studies will provide important tests of immune and inflammatory mechanisms of MS disease...
  17. ncbi request reprint Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
    Robert J Fox
    Department of Neurology Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 11:140-5. 2005
    ....
  18. doi request reprint Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
    J A Cohen
    Mellen Center U 10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:535-41. 2009
    ..v. methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNbeta-1a monotherapy...
  19. doi request reprint Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
    ....
  20. ncbi request reprint Multiple sclerosis: treating symptoms, and other general medical issues
    Myla D Goldman
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 73:177-86. 2006
    ..Clinicians can have an important impact on health, quality of life, and daily functioning by participating in open dialogue, tailoring focused treatment plans, and anticipating general medical needs...
  21. ncbi request reprint Imaging correlates of axonal swelling in chronic multiple sclerosis brains
    Elizabeth Fisher
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland, OH 44195, USA
    Ann Neurol 62:219-28. 2007
    ....
  22. ncbi request reprint Immunological studies of mitoxantrone in primary progressive MS
    Clara M Pelfrey
    Department of Neurosciences NC30, Lerner Research Institute, Lerner College of Medicine of Case Western Reserve University, 9500 Euclid Ave, Cleveland, OH, USA
    J Neuroimmunol 175:192-9. 2006
    ..An improved understanding of MX may help identify markers of disease activity and response to therapy...
  23. doi request reprint Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy
    Robert A Bermel
    Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA
    Mult Scler 16:1335-40. 2010
    ..In this study we review our experience with patients diagnosed at age 60 or over, with particular emphasis on patients who continue to have evidence of active inflammation despite a later onset...
  24. pmc Web-based self-management for patients with multiple sclerosis: a practical, randomized trial
    Deborah M Miller
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Telemed J E Health 17:5-13. 2011
    ....
  25. doi request reprint B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
    Stephen L Hauser
    Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0114, USA
    N Engl J Med 358:676-88. 2008
    ..There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes...
  26. ncbi request reprint Multiple sclerosis: disease markers accelerate progress
    Robert J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH, Cleveland, USA
    Lancet Neurol 3:10. 2004
  27. pmc Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis
    Natalia M Moll
    Neuroinflammation Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Arch Neurol 66:44-53. 2009
    ..We studied the following ROIs: normal-appearing white matter (NAWM); regions abnormal only on T2-weighted images (T2 only); and regions abnormal on T2- and T1-weighted images with an abnormal magnetization transfer ratio (T2/T1/MTR)...
  28. doi request reprint Picturing multiple sclerosis: conventional and diffusion tensor imaging
    Robert J Fox
    Mellen Center for Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Semin Neurol 28:453-66. 2008
    ..Evidence from animal models suggests that DTI may differentiate axonal injury from demyelination and therefore may be useful in the evaluation of neuroprotective therapies...
  29. ncbi request reprint Mitoxantrone as a potential therapy for primary progressive multiple sclerosis
    Olaf Stuve
    Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C 440, San Francisco, CA 94143 0114, USA
    Mult Scler 10:S58-61. 2004
    ..Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article...
  30. ncbi request reprint Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis
    Don Mahad
    Department of Neurosciences, The Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Brain 129:212-23. 2006
    ....
  31. ncbi request reprint Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
    Ranjan Dutta
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 59:478-89. 2006
    ..Development of neuroprotective therapies will require elucidation of the molecular mechanisms by which neurons and axons degenerate...
  32. pmc Neurogenesis in the chronic lesions of multiple sclerosis
    Ansi Chang
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Brain 131:2366-75. 2008
    ..These results support neurogenesis in a subpopulation of demyelinated subcortical white matter lesions in multiple sclerosis brains...
  33. pmc Chemokine receptors as biomarkers in multiple sclerosis
    Robert J Fox
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH 44122, USA
    Dis Markers 22:227-33. 2006
    ..Evaluation of chemokines or chemokine receptors as biomarkers in MS will need to account for this individual variability in CKR expression...
  34. ncbi request reprint Is natalizumab overshooting its rebound?
    Robert J Fox
    Neurology 70:1073-4. 2008
  35. doi request reprint Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial
    Amit Bar-Or
    Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Ann Neurol 63:395-400. 2008
    ..Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy...
  36. ncbi request reprint Disease modifying therapies in multiple sclerosis
    Robert J Fox
    Neurology 59:471-2; author reply 472-3. 2002
  37. ncbi request reprint The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis
    Robert J Fox
    Neurology 58:1576; author reply 1576. 2002
  38. ncbi request reprint Defending eponyms
    Robert J Fox
    Arch Neurol 63:628. 2006

Research Grants2

  1. Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis
    Robert Fox; Fiscal Year: 2007
    ..Furthermore, these studies should help develop improved methods for evaluating new therapeutic strategies for neuroprotection and neuroregeneration. ..